CRISPR- based epigenetic editing: A new era of disease control without gen, A review

CRISPR-based epigenetic editing is a revolutionary technique that enables precise control of gene expression without altering the underlying DNA sequence. This approach uses a modified CRISPR/Cas9 system, where the nuclease activity of Cas9 is inactivated (dCas9) and fused with epigenetic effector proteins to modify chromatin structure or DNA methylation at specific genomic loci. By targeting regulatory regions of genes, this method allows for activation or repression of gene function in a reversible and controlled manner. Unlike traditional genome editing, which involves permanent changes in DNA, epigenetic editing offers a safer and more flexible alternative for therapeutic interventions.

This project focuses on the principles, mechanisms, and applications of CRISPR-based epigenetic editing in disease control. It highlights its potential in treating complex conditions such as cancer, neurological disorders, cardiovascular diseases, and metabolic syndromes, where abnormal gene expression plays a key role. The technology’s non-permanent nature, high specificity, and adaptability make it an essential tool in modern biotechnology and personalized medicine. By providing a deeper understanding of its advantages, challenges, and future prospects, this study emphasizes CRISPR-based epigenetic editing as a promising approach for next-generation therapies.